Elicio Therapeutics Inc. CEO Robert Connelly acknowledged "a general malaise about cancer vaccines," but described the strategy of his firm to BioWorld as "very different. None of these other approaches [has] delivered the goods to the lymph nodes, where the immune response is orchestrated."